DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/pz44tp/epigenetic) has announced the addition of the "Epigenetic Therapy in Oncology Drug Pipeline Update 2013" report to their offering.

Improper gene activation or silencing by loss of epigenetic control can lead to aberrant gene expression that can drive the development of diseases such as cancer, autoimmunity, diabetes, or neurological disorders. Recent research has identified the set of enzymes and chromatin-binding proteins responsible for regulating chromatin structure. These enzymes and binding proteins form the cell's toolkit for epigenetic regulation by opening and closing chromatin or modifying chromatin structure to help control when and where genes are expressed. Inhibiting these targets with emerging drugs promises to be a powerful avenue to develop important treatments serving unmet medical needs.

There are today 60 companies plus partners developing 70 epigenetic therapy drugs in 253 developmental projects in cancer. In addition, there is 1 suspended drug and the accumulated number of ceased drugs over the last years amount to another 23 drugs.

Epigenetic Therapy In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 36 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 34 out of the 35 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information.

All drugs targets are further categorized on in the software application by 14 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.

Reasons To Buy

- Show investors/board/management that you are right on top of drug development progress in your therapeutic area.

- Find competitors, collaborations partners, M&A candidates etc.

- Jump start competitive drug intelligence operations

View post:
Research and Markets: Epigenetic Therapy in Oncology Drug Pipeline Update 2013

Comments are closed.